|1.||Ross, Daniel E: 1 article (09/2005)|
|2.||Swaney, Steve M: 1 article (09/2005)|
|3.||Nagiec, Eva E: 1 article (09/2005)|
|4.||Brieland, Joan K: 1 article (09/2005)|
|5.||Leach, Karen L: 1 article (09/2005)|
|6.||Wu, Luping: 1 article (09/2005)|
|7.||Chosay, John G: 1 article (09/2005)|
|8.||Fleming, Gerard: 1 article (10/2003)|
|9.||Curtin, John: 1 article (10/2003)|
|10.||Cormican, Martin: 1 article (10/2003)|
03/09/2000 - "pneumoniae in mouse models of human infection with ED(50)s in the range of 1. 2-1.9 mg/kg versus 2.8-4.0 mg/kg for the eperezolid (1) control."
12/01/1999 - "faecium infections, intravenous eperezolid and oral linezolid were effective, reducing densities approximately 2 log(10) CFU/g. "
06/01/1996 - "In several mouse models of methicillin-resistant Staphylococcus aureus infection, U-100592 and U-100766 yielded oral 50% effective doses (ED50) ranging from 1.9 to 8.0 mg/kg of body weight, which compared favorably with vancomycin subcutaneous ED50 values of 1.1 to 4.4 mg/kg. Similarly, both compounds were active versus a Staphylococcus epidermidis experimental systemic infection. "
06/01/1996 - "U-100592 and U-100766 effectively cured an Enterococcus faecalis systemic infection, with ED50 values of 1.3 and 10.0 mg/kg, and versus a vancomycin-resistant Enterococcus faecium infection in immunocompromised mice, both drugs effected cures at 12.5 and 24.0 mg/kg. Both compounds were exceptionally active in vivo against penicillin- and cephalosporin-resistant Streptococcus pneumoniae, with ED50 values ranging from 1.2 to 11.7 mg/kg in systemic infection models. "
10/01/2003 - "Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections."
12/01/1999 - "The in vivo effectiveness of oxazolidinones eperezolid (U-100592) and linezolid (U-100766) against one strain each of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium was examined in a rat model of intra-abdominal abscess. "
12/01/1999 - "Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium."
|3.||Soft Tissue Infections
|4.||Gram-Positive Bacterial Infections
02/02/1996 - "We have prepared two potent, synthetic oxazolidinones, U-100592 and U-100766, which are currently in clinical development for the treatment of serious multidrug-resistant Gram-positive bacterial infections caused by strains of staphylococci, streptococci, and enterococci. "
02/02/1996 - "Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections."
|4.||Oxazolidinones (2 Oxazolidone)
|8.||Anti-Bacterial Agents (Antibiotics)
|9.||Anti-Infective Agents (Microbicides)